Rivoceranib mesylate

Rivoceranib Mesylate is the mesylate salt of rivoceranib, an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. Additionally, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. It is grouped under the following drug class(es): Tyrosine Kinase Inhibitors and VEGF inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Apatinib Mesylate, Aitan and YN968D1. Its PubChem CID is 45139106.

CAS No 1218779-75-9
Molecular Formula C25H27N5O4S
Molecular Weight 493.6 g/mol
Synonyms N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic acid

Frequently Asked Questions